Stage III Prostate Cancer AJCC v8 Clinical Trial
Official title:
ART of SABR: A Randomized Phase II Trial of Near "Margin-Less" Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two Versus Five Fractions
Verified date | March 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. It may be able to deliver radiation to the site of disease over a shorter time and with smaller margins (less treatment delivered to nearby healthy tissues). SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Shorter duration near margin-less ART may be just as effective at treating patients with localized prostate cancer but have less quality of life side effects than standard SABR.
Status | Not yet recruiting |
Enrollment | 144 |
Est. completion date | June 2026 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Gender assigned male at birth: age = 18 years - Histological confirmation of prostate adenocarcinoma - National Comprehensive Cancer Network (NCCN) (Prostate Cancer version 4.2022) low- to intermediate-risk prostate adenocarcinoma - Eastern Cooperative Oncology Group (ECOG) performance status = 2 - Ability to complete questionnaire(s) by themselves or with assistance - Signed informed consent - Willing to complete requirements for follow-up (during active monitoring phase) Exclusion Criteria: - NCCN (Prostate Cancer version 4.2022) very low-, high-, or very high-risk prostate adenocarcinoma - Prior definitive treatment of prostate cancer including radiotherapy, prostatectomy, cryotherapy, or high intensity focused ultrasound (HIFU) - Prior bladder outlet obstruction procedures including transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), transurethral vaporesection of the prostate (TUVRP), etc. - Metastatic disease by conventional or molecular imaging - Contraindications to radiation therapy (RT) including uncontrolled inflammatory bowel disease, ATM mutation, and Xeroderma pigmentosum mutation - Concurrent antineoplastic agents (chemotherapy) - Previous or concurrent malignancy other than non-melanoma skin cancer, indolent lymphoma, or chronic myelogenous leukemia, unless continuously disease-free = 5 years - Medical or psychiatric conditions that preclude informed decision-making or adherence with the protocol-defined treatment or follow-up - Prostate gland volume > 80 cc based on magnetic resonance imaging (MRI), and/or International Prostate Symptom Score (IPSS) composite score > 17 - Body weight > 200 kilogram |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment-related, patient-reported early quality of life (QOL) changes | Will be assessed using the Expanded Prostate Cancer Index Composite (EPIC)-26. The EPIC-26 consists of 13 questions answered on a variety of scales, such as 1-5 where 1=very poor and 5=very good. | Baseline; up to 3 months | |
Secondary | Treatment-related, patient-reported late QOL changes | Will be assessed using the EPIC-26 questionnaire, as described above. | Baseline; up to 24 months | |
Secondary | Incidence of grade = 2 genitourinary an/or gastrointestinal adverse events | Incidence of adverse events will be recorded at study visits. An adverse event is defined as any undesirable experience associated with the use of a medical product in a patient. | Up to 24 months | |
Secondary | Change in International Index of Erectile Function (IIEF) | The IIEF consists of 15 questions answered with various scales (e.g., a scale of 5-1 where 5=almost always or always and 1=almost never or never). Possible scores range from 5 to 25, and erectile dysfunction (ED) is classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25). | Baseline; up to 24 months | |
Secondary | Change in International Prostate Symptom Score (IPSS) | The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life.Each question is answered on a scale of 0-5 where 0=not at all/none and 5=almost always/5 5times. | Baseline; up to 24 months | |
Secondary | Change in financial adverse events - COST-FACIT | Change in financial adverse events will be assessed using the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) assessment tool. The COST-FACIT consists of 12 questions, each answered on a scale of 0-4 where 0=not al all and 4=very much. | Baseline; 12 months | |
Secondary | Fiducial-free treatment | Will evaluate associations of fiducial-free treatment on dosimetry, patient reported outcomes (PROs), and toxicity. A fiducial is medical device or small object placed in or on the body to mark an area for radiation treatment or surgery. For example, tiny gold seeds may be put into the prostate to mark a tumor before radiation therapy. | Up to 5 years | |
Secondary | Bladder filling | Will evaluate associations of bladder filling on dosimetry, patient reported outcomes (PROs), and toxicity using Fisher's exact test and the nonparametric Wilcoxon sum rank test. | Up to 5 years | |
Secondary | Biochemical recurrence | Biochemical disease recurrence will be estimated using the Kaplan-Meier method and compared using the log-rank test for each timepoint. Biochemical failure is defined as a prostate-specific antigen (PSA) value that is = PSA nadir + 2.0 ng/mL with the date of biochemical failure set at the date of the PSA value that meets this criterion. | At 2 and 5 years | |
Secondary | Prostate specific antigen (PSA) kinetics | Median PSA nadir as well as median time to nadir will be reported | Up to 5 years | |
Secondary | Local recurrence | Local recurrence is defined as Magnetic Resonance Imaging (MRI) or prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/Computed Tomography (CT) evidence of recurrence disease in conjunction with biochemical failures. | Up to 5 years | |
Secondary | Overall survival | Survival duration will be measured from the date of registration to the date of death from any cause. | From the date of registration to the date of death from any cause, assessed up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03218826 -
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT04981834 -
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
|
N/A | |
Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
Recruiting |
NCT06173362 -
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
|
Phase 2 | |
Suspended |
NCT03899987 -
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
|
Phase 2 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Not yet recruiting |
NCT06129851 -
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05487846 -
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
|
N/A | |
Recruiting |
NCT05946213 -
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03570827 -
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
|
Phase 2 | |
Recruiting |
NCT03987386 -
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT04134260 -
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
|
Phase 3 | |
Completed |
NCT03177460 -
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05320406 -
RElugolix VErsus LeUprolide Cardiac Trial
|
Phase 4 | |
Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
Suspended |
NCT04037254 -
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05869682 -
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
|
Phase 2 | |
Recruiting |
NCT06389786 -
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
|
N/A | |
Recruiting |
NCT05877144 -
Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery
|
N/A | |
Completed |
NCT03784677 -
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
|
Phase 1 |